> [1] Wouldn't it be worth funding this company just to find this out about Parkinson's disease?
Only if they plan to branch out from genotyping into other areas of science, as the article describes how their research shows the limits of this approach in Parkinson's disease.
Maybe they only do the genotyping and other people can handle other aspects of disease prediction and prevention. Knowing something doesn't predict something else is just as good as knowing it does. In either case you need more information, but you've learned something.
Comments
> [1] Wouldn't it be worth funding this company just to find this out about Parkinson's disease?
Only if they plan to branch out from genotyping into other areas of science, as the article describes how their research shows the limits of this approach in Parkinson's disease.
Maybe they only do the genotyping and other people can handle other aspects of disease prediction and prevention. Knowing something doesn't predict something else is just as good as knowing it does. In either case you need more information, but you've learned something.